Loading...
XSHE300558
Market cap3.19bUSD
Jan 17, Last price  
55.91CNY
1D
5.13%
1Q
23.15%
Jan 2017
-24.24%
IPO
100.90%
Name

Betta Pharmaceuticals Co Ltd

Chart & Performance

D1W1MN
XSHE:300558 chart
P/E
67.23
P/S
9.53
EPS
0.83
Div Yield, %
0.47%
Shrs. gr., 5y
1.09%
Rev. gr., 5y
14.94%
Revenues
2.46b
+3.35%
62,831,356312,384,705480,697,986704,435,260914,663,8731,035,060,8991,026,358,6561,224,171,7681,553,924,2551,870,266,3142,245,855,5912,376,629,6572,456,196,486
Net income
348m
+139.33%
17,557,066104,898,840178,398,819269,286,149345,298,066368,795,897257,727,409166,818,363230,821,620606,360,588383,067,840145,420,319348,032,472
CFO
914m
+198.05%
34,799,693149,286,782190,342,024277,553,769385,563,833407,053,018278,257,560286,396,896555,074,095646,022,131526,630,893306,739,633914,227,977
Dividend
Jun 06, 20240.17 CNY/sh
Earnings
May 15, 2025

Profile

Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib hydrochloride, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat non-small-cell lung cancer; and Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer. Betta Pharmaceuticals Co., Ltd. was founded in 2003 and is headquartered in Hangzhou, China.
URL
https://www.bettapharma.com/
IPO date
Nov 07, 2016
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,456,196
3.35%
2,376,630
5.82%
Cost of revenue
1,741,181
2,064,430
Unusual Expense (Income)
NOPBT
715,015
312,200
NOPBT Margin
29.11%
13.14%
Operating Taxes
(11,541)
Tax Rate
NOPAT
726,557
312,200
Net income
348,032
139.33%
145,420
-62.04%
Dividends
(110,283)
(103,847)
Dividend yield
0.51%
0.51%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
606,124
1,101,354
Long-term debt
1,832,366
670,626
Deferred revenue
144,703
112,765
Other long-term liabilities
1
Net debt
270,362
88,747
Cash flow
Cash from operating activities
914,228
306,740
CAPEX
(1,096,014)
Cash from investing activities
(1,505,453)
Cash from financing activities
608,193
941,520
FCF
192,298
(413,145)
Balance
Cash
752,536
731,285
Long term investments
1,415,591
951,948
Excess cash
2,045,318
1,564,401
Stockholders' equity
3,406,021
3,097,694
Invested Capital
5,881,165
5,249,642
ROIC
13.05%
6.59%
ROCE
8.99%
4.53%
EV
Common stock shares outstanding
419,316
415,487
Price
51.55
4.63%
49.27
-38.28%
Market cap
21,615,752
5.59%
20,471,026
-38.27%
EV
21,986,510
20,668,414
EBITDA
1,018,503
565,901
EV/EBITDA
21.59
36.52
Interest
54,955
195,801
Interest/NOPBT
7.69%
62.72%